Literature DB >> 27781408

Pathology of healing: what else might we look at?

Yoshiya Horimoto1,2, Takuo Hayashi3, Atsushi Arakawa3.   

Abstract

Several aspects of the article by Morita et al. (Cancer Medicine 5:1607-18, 2016), examining the spontaneous healing phenomenon with reference to tumor infiltrating lymphocytes (TILs), require clarification. The concept of "healing", which can perhaps be more accurately termed "regressive change", remains controversial due to a lack of concrete evidence. Since regressive change is characterized by fibrosis and lymphocytes, a cancer nest that appears to lack a distinct basement membrane, surrounded only by lymphocytes, as in Morita et al's Figure 2F, should be meticulously examined because the appearance may correspond to a tumor having just completed the process of invasion. In our experience, a layer of myoepithelial cells in such foci is often difficult to detect even with immunohistochemistry. Thus, we suggest evaluating the viability of cancer cells within the nest by employing several markers, such as Ki67 and apoptotic markers, to judge whether the tumor is intraductal. It might also be useful to compare cases with versus without regressive change to elucidate the biology of such tumors. For these reasons, a tumor, floating within a pool of TILs and lacking obvious fibrous bands, might be an interesting material to examine in future studies.
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990DCISzzm321990; Breast cancer; healing; tumor infiltrating lymphocytes

Mesh:

Year:  2016        PMID: 27781408      PMCID: PMC5224836          DOI: 10.1002/cam4.952

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


We read with interest the Morita et al. article 1, which described the spontaneous healing phenomenon of ductal carcinoma in situ (DCIS) with reference to tumor infiltrating lymphocytes (TILs), in an effort to elucidate the biology of DCIS and immune cells. While taking an interesting approach, several aspects of this study require clarification. The “healing” concept has been recognized for more than 80 years 2. However, it has not yet been widely accepted by pathologists. “Healing”, which can perhaps be more accurately termed “regressive change” 3, 4, remains controversial due to lack of concrete evidence. The most uncomfortable aspect of this issue for many pathologists is a cancer nest, surrounded by lymphocytes with an apparent lack of basement membrane, being recognized as undergoing a process leading to cell death. Furthermore, this process is seemingly mediated by immune cells. Worryingly, however, this appearance of cancer cells may also correspond to a tumor having just completed the process of invasion. We regard this as a major concern, since the diagnosis and management would be completely different in these two circumstances. As described by Hoda 5, we understand that the process of regressive change is characterized by fibrosis and infiltration of lymphocytes constituting an inflammatory reaction by the host. Thus, a cancer nest that appears to lack a distinct basement membrane, surrounded only by lymphocytes, as in figure 2F by Morita et al. 1, should be meticulously examined. Although Morita et al. stated that they confirmed the presence of myoepithelial cells by p63 immunostaining in foci of uncertain malignancy, in our experience, a layer of myoepithelial cells in such foci is often difficult to detect even when employing immunohistochemistry (IHC) for a panel of myoepithelial cell markers such as p63 and CD10. Thus, we suggest evaluating the viability of the cancer cells within the nest by employing several markers, such as Ki67 and apoptotic markers. If an intraductal lesion recedes during the process of regressive change, the cancer cells should show low Ki67 expression and a high number of apoptotic events, while the reverse would be true for invasive disease. IHC targeting cleaved‐Caspase 3 detects cancer cells undergoing apoptosis, even before the manifestation of morphological changes such as apoptotic body formation. Previous studies employed this method 6, 7, 8 and Pape‐Zambito et al. revealed a positive correlation between Ki67 and cleaved‐Caspase 3 in DCIS 6. We recently showed cleaved‐Caspase 3 to predict poor outcomes in patients who received neoadjuvant chemotherapy 9. Although surgical specimens after chemotherapy, quite different from DCIS, were used in that study, we believe that this protein might still be useful for evaluating DCIS. While establishing the viability of cancer cells as a method of judging whether a tumor remains intraductal requires well‐designed future studies, it might also be useful to compare cases with versus without regressive change to elucidate the biology of such tumors. CD8‐positive T cells, which have a primary role in cellular immunity, might need to be in direct contact with cancer cells, rather than exerting their effects through thick fibrous bands. Humoral immunity, which involves mainly B cells, might become dominant once thick fibrous bands have formed. For these reasons, the TIL population surrounding a cancer nest may change in accordance with the observed stages of regressive change, as defined by the authors. Thus, TILs including CD8‐potisive T cells should be evaluated according to these stages. Focusing on TILs is very interesting as various studies have recently revealed numerous mechanisms of cancer immune‐editing. While strong TIL invasion has been reported to be related to better patient outcomes 10, 11, cancer cells themselves can reportedly induce an escape phase by means of gathering regulatory T cells 12. A tumor, floating within a pool of TILs and lacking obvious fibrous bands, might well be the most interesting material to examine in future studies, for the reasons described above.

Conflict of Interest

None declared.
  10 in total

1.  Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance.

Authors:  Jason K Wasserman; Carlos Parra-Herran
Journal:  Am J Clin Pathol       Date:  2015-09       Impact factor: 2.493

Review 2.  Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications.

Authors:  Mamatha Chivukula; Akosua Domfeh; Gloria Carter; George Tseng; David J Dabbs
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-12

3.  Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.

Authors:  Henry M Kuerer; Aman U Buzdar; Elizabeth A Mittendorf; Francisco J Esteva; Anthony Lucci; Luis M Vence; Laszlo Radvanyi; Funda Meric-Bernstam; Kelly K Hunt; William Fraser Symmans
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

4.  Activated Caspase 3 Expression in Remnant Disease After Neoadjuvant Chemotherapy May Predict Outcomes of Breast Cancer Patients.

Authors:  Takanori Himuro; Yoshiya Horimoto; Atsushi Arakawa; Joe Matsuoka; Emi Tokuda; Masahiko Tanabe; Mitsue Saito
Journal:  Ann Surg Oncol       Date:  2016-03-01       Impact factor: 5.344

5.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 6.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

Authors:  M J M Gooden; G H de Bock; N Leffers; T Daemen; H W Nijman
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

7.  Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.

Authors:  Dana Pape-Zambito; Zhengyu Jiang; Hong Wu; Karthik Devarajan; Carolyn M Slater; Kathy Q Cai; Arthur Patchefsky; Mary B Daly; Xiaowei Chen
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

8.  Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Authors:  Yunn-Yi Chen; Sandy DeVries; Joseph Anderson; Juan Lessing; Rebecca Swain; Koei Chin; Veronica Shim; Laura J Esserman; Frederic M Waldman; E Shelley Hwang
Journal:  BMC Cancer       Date:  2009-08-18       Impact factor: 4.430

9.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Authors:  Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

10.  CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.

Authors:  Michi Morita; Rin Yamaguchi; Maki Tanaka; Gary M Tse; Miki Yamaguchi; Naoki Kanomata; Yoshiki Naito; Jun Akiba; Satoshi Hattori; Shigeki Minami; Susumu Eguchi; Hirohisa Yano
Journal:  Cancer Med       Date:  2016-04-06       Impact factor: 4.452

  10 in total
  1 in total

1.  Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer.

Authors:  Shiyuan Wang; Yakun Wang; Chunlu Yu; Yiyin Cao; Yao Yu; Yi Pan; Dongqing Su; Qianzi Lu; Wuritu Yang; Yongchun Zuo; Lei Yang
Journal:  J Cell Mol Med       Date:  2020-04-05       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.